Preclinical development and qualification of ZFN-mediated CCR5 disruption in human hematopoietic stem/progenitor cells.

Mol Ther Methods Clin Dev · 2016 · PMC5102145 · PMID 27900346

Europe PMC DOI

hedged sentence

0.2000

closest p · 4.0× alpha

0.2000

boldest claim

The sentences

did not reach statistical significanceP = 0.2not close (p > 0.1)

Tumorigenicity study: general findings Survival to the time-point of tumorigenicity study termination was 95% (57/60) in the control group and 86% (136/158) in the mice that received SB-728mR- HSPC; this difference did not reach statistical significance ( P = 0.2; Mann–Whitney U -test).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.